GeoVax to Participate in Upcoming November Investor and Industry Events
25 Outubro 2023 - 10:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced that
members of its senior management team and other scientific
representatives will participate in four upcoming investor and
industry events during November. Event details are as follows:
Emerging Growth Conference, November 1-2, 2023,
VirtualDate/Time: November 2, 2023 at
3:55 p.m. ETTitle:
GeoVax Corporate UpdateSpeaker:
David Dodd, Chairman & CEO, GeoVax Labs, Inc.For
more information and to register to attend the GeoVax Presentation,
please visit Emerging Growth Conference.
BIO-Europe, November 6-8, 2023, Munich,
GermanySenior GeoVax management will host one-on-one
meetings with registered attendees. For more information, please
visit Bio-Europe. If interested in meeting with management at this
event, please contact the company through the conference portal, or
directly at info@geovax.com.
Vaccines Summit 2023, November 13-15, 2023, Boston,
MADate/Time: November 14, 2023 at
8:00 a.m. ETSession Title: MVA-vectored
multi-antigen COVID-19 vaccines induce protective immunity against
SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal
modelsSpeaker: Mukesh Kumar, PhD, Associate
Professor, Department of Biology, Georgia State UniversityFor more
information on the conference, please visit Vaccines Summit
2023.
World Vaccine Congress, West Coast, November 27-30,
2023, Santa Clara, CADate/Time: November
28, 2023 at 4:20 p.m. PTSession Title: COVID-19
Vaccines for immunocompromised patientsSpeaker:
Don Diamond, Professor, Department of Hematology and Hematopoietic
Cell Transplantation, City of Hope Comprehensive Cancer Center
Date/Time: November 30, 2023 at 1:40 p.m.
PTSession Title: Design and evaluation of vaccines
against hemorrhagic fevers using the MVA-VLP
platformSpeaker: Jason Comer, PhD, Associate
Professor, Department of Microbiology and Immunology, University of
Texas Medical BranchFor more information on the conference, please
visit World Vaccine Congress, West Coast.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in three Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a primary vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient, and as a booster vaccine in patients
with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is
in a Phase 2 clinical trial evaluating the vaccine as a more
robust, durable COVID-19 booster among healthy patients who
previously received the mRNA vaccines. GeoVax has a leadership team
who have driven significant value creation across multiple life
science companies over the past several decades. For more
information, visit our website: www.geovax.com.
Company
Contact: |
|
Investor Relations
Contact: |
|
Media
Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
|
|
|
|
|
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024